The purpose of this observational study is to describe the demographics, and disease characteristics of participants with metastatic upper gastrointestinal cancer, along with the treatment characteristics of these patients when treated with nivolumab.
Study Type
OBSERVATIONAL
Enrollment
700
As per product label
Bayshore Specialty Rx Ltd.
Mississauga, Ontario, Canada
Particpant sociodemographics
Time frame: Baseline
Participant Eastern Cooperative Oncology Group (ECOG) score
Time frame: Baseline
Participant HER2 status
Time frame: Baseline
Participant comorbidities
Time frame: Baseline
Participant tumour location
Time frame: Baseline
Participant treatment history
Time frame: Baseline
Initial nivolumab dosage prescribed to participants
Time frame: Index date
Number of nivolumab treatments received by participants
Time frame: Up to 75 weeks
Planned combination chemotherapy treatment
Time frame: Index date
Nivolumab treatment initiation date
Time frame: Index date
Nivolumab dosage modification
Time frame: Up to 75 weeks
Participant treatment duration
Time frame: Up to 75 weeks
Reason for participant discharge
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Up to 75 weeks
Participant adverse events (AEs)
Time frame: Up to 75 weeks
Management of participant adverse events (AEs)
Time frame: Up to 75 weeks